No ASX ETF holds Mayne Pharma (MYX) as of 15 Oct 2026. Over the last year it fell 60.5%: on $10,000, −$6048. We explain 18 big moves in that time.
About MYX
- SectorHealth Care
- IndustryPharmaceuticals, Biotechnology & Life Sciences
- Size$208.0m
- Held by0 ETFs
- Big moves18 in 1Y
Each dot is a move we explain. Tap one, or a row of Why it moved, to see what caused it.
Why it moved
- −5.7%10 Sep 2026· No Catalyst Found
MYX fell alongside a broad healthcare sector sell-off, with the ASX health index down 2.3% and 36 industry peers down a median 2.3% on the same day.
- +10.2%peak +11.3%3 Aug 2026· Sector Flow
MYX.AX rose sharply alongside a broad rally in the ASX healthcare sector, which gained over 2.3% on the same day, lifting sentiment across health-related stocks.
- +7.5%27 Jun 2026· Sector Flow
The stock price rise appears to be part of a broader positive move in healthcare stocks, with no company-specific news identified.
- +6.7%30 Apr 2026· Earnings Beat
Mayne Pharma reported a strong Q3 update, driving shares up approximately 8%.
- −6.5%9 Apr 2026· Sector Flow
No clear company-specific news on the price move date; likely broad healthcare sector weakness or profit-taking after tariff-related reassurances.
- −8.2%19 Mar 2026· Unknown
No relevant news articles directly explain the 8.19% decline in Mayne Pharma Group on 2026-03-18, leaving the cause unknown.
- −9.4%12 Mar 2026· Unknown
Likely investor reaction to the company's U.S. launch and business model presentation of DistributeRx, which may have raised concerns about costs or execution risks.
- +7.3%11 Mar 2026· Operational
Mayne Pharma hosted a business presentation discussing the U.S. launch and business model of DistributeRx, which was well-received by the market.
- +5.6%10 Mar 2026· Operational
Mayne Pharma discussed the U.S. launch and business model of DistributeRx, likely boosting investor sentiment.
- −7.9%9 Mar 2026· Unknown
No direct news explaining the 7.87% drop was found; the price move appears unexplained by available articles.
- −9.5%12 Feb 2026· Unknown
Insufficient evidence to determine the cause of the price drop.
- −6.6%2 Dec 2025· Unknown
Insufficient evidence to determine the cause of the abnormal price move.
- −18.0%24 Nov 2025· Takeover / M&A
The Australian government objected to the takeover of Mayne Pharma by Cosette, causing the stock to drop sharply.
- +20.9%20 Nov 2025· Takeover / M&A
Mayne Pharma stock surged 20.88% on news of a takeover bid, despite the Australian government later blocking the Cosette acquisition on national interest grounds.
- +5.9%5 Nov 2025· Unknown
Insufficient evidence to determine a specific cause for the price move.
- +7.5%3 Nov 2025· Unknown
No public news was found, so the cause cannot be determined.
- −31.5%31 Oct 2025· Unknown
No news articles were found to explain the price movement.
- +11.3%16 Oct 2025· Takeover / M&A
Court blocked Cosette's attempt to terminate the $438 million takeover deal, clearing a major regulatory hurdle.
Held by 0 ETFs
No ETF we track holds MYX directly.
Other Health Care companies
- SHLSonic Healthcare47 ETFs
- RMDResMed44 ETFs
- CSLCSL Limited42 ETFs
- BDXBcal36 ETFs
- CSXCleanspace36 ETFs
- REGRegis Health33 ETFs
- TLXTelix Pharma32 ETFs
- SIGSigma Healthcare31 ETFs
Why did MYX rise 7.5% on 27 Jun 2026?
Mayne Pharma
The stock price rise appears to be part of a broader positive move in healthcare stocks, with no company-specific news identified.
The news article from the following Monday highlights a 3.89% rise, but the primary driver referenced is general healthcare sector momentum. No company-specific announcements, such as earnings, contracts, or M&A, were found in the provided articles around the event date. The price move and volume spike are consistent with sector-wide buying rather than a stock-specific catalyst.
Written by a language model from the evidence below, and it can be wrong. Tell us and we will fix or remove it. General information only, not financial product advice. It does not consider your objectives, finances or needs. Past performance is not a guide to future performance.
Evidence
News coverage